Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 1 | EJNMMI Radiopharmacy and Chemistry

Fig. 1

From: Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu

Fig. 1

a Surviving fraction of human PANC-1 cells exposed to 0.3, 0.6 or 1.2 MBq (2.5 nmoles/L) of panitumumab-DOTA-[111In]In, panitumumab-MCP-[111In]In, or panitumumab-DOTA-[177Lu]Lu or unlabeled radioimunoconjugaes (RICs; 0.0 MBq) in 2.0 mL of growth medium. Values shown are the mean ± SD (n = 3). Significant differences (P < 0.05) are noted by asterisks. b Surviving fraction of PANC-1 cells exposed to RICs vs. absorbed dose (Gy) in the nucleus. Absorbed dose was calculated as described in the Methods and shown in Table 1. The data was fitted to a survival model: SF = exp.(−a*dose). Fitting revealed that a = 1.19 ± 0.23 for panitumumab-MCP-[111In]In; 0.37 ± 0.08 for panitumumab-DOTA-[111In] and 0.56 ± 0.11 for panitumumab-DOTA-[177Lu]Lu

Back to article page